Drug Discovery World

AUGUST 10, 2022

And now, with more than 600 CAR T trials recruiting or ongoing, these cells represent a majority of the cellular immunotherapies in development today. As a result, the global CAR T cell market may reach $8 billion in size by 2028 23.With Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.

Therapies 246

Therapies Virus Treatment Engineering 246

Drug Discovery World

SEPTEMBER 28, 2022

In fact, the market research firm, Bekryl, predicts that AI has the potential to offer over $70 billion in savings for the drug discovery process by 2028. . The significance of these predictions has not been lost on investors in the health and technology space. billion in 2021, an increase of 79% from 2020.

Pharma Companies 130

Pharma Companies Hospitals Clinical Trials Drugs 130

The Pharma Data

JANUARY 19, 2021

TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. TC-110 is in a Phase I/II trial for CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

Small Molecule 52

Small Molecule Laboratories Immune Response Trials 52

Agency IQ

MAY 28, 2024

It would also introduce new requirements for human clinical trials, post-market surveillance and vigilance. CE mark in addition to its own UKCA mark, with a plan to continue doing so through 2028 or 2030, depending on the legislation to which the CE mark applies. Notably, IVDs would be regulated under the same proposed regulation.

International 40

International Regulations Licensing Licensing 40

The Premier Consulting Blog

NOVEMBER 20, 2023

Clinical development experts would need to navigate the potential complexities arising from this regulatory shift, particularly in terms of trial design and evidence generation. For regulatory affairs specialists, this implies heightened diligence to ensure that LDTs align with premarket review standards.

Laboratories 52

Laboratories FDA Clinical Development Regulations 52

Agency IQ

JANUARY 26, 2024

EMA regulators themselves published an article discussing the review process for companion diagnostics and the lack of opportunity to use a single submission for the drug clinical trial under the Clinical Trial Regulation and the performance study application according to the IVDR.

Regulations 40

Regulations Compliance Laboratories Production 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. A Phase 3 trial is ongoing.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2020

It is estimated that there will potentially be 13 million moderate-to-severe acne patients treated with oral antibiotics in the urban Chinese population by 2028, which represents a significant opportunity to launch an innovative product whose clinical development is largely de-risked.

Licensing 52

Licensing Licensing Production Marketing 52

Agency IQ

FEBRUARY 2, 2024

Companion diagnostics (CDx) and cancer trials: In 2023, the MDCG published guidance documents on classifying CDx. This remains a major area of concern for both industry and regulators, with a March 2023 survey from EFPIA finding that the challenges with the IVDR has led to issues with IVDs used in drug trials , and particularly cancer trials.

FDA 40

FDA Regulations Laboratories Production 40

The Pharma Data

JANUARY 25, 2021

Prior to November 1, 2028, the notes will be convertible only upon satisfaction of certain conditions and during certain periods. The notes will bear interest at a rate of 2.25% per year, payable semi-annually in arrears on February 1 and August 1 of each year, beginning August 1, 2021.

Marketing 52

Marketing Disease Clinical Trials Production 52

The Pharma Data

JANUARY 9, 2021

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the impact of global economic conditions and public health crises and epidemics, such as the global pandemic that arose from COVID-19, on the markets, our operations, and employees as well (..)

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

NOVEMBER 4, 2020

Reaffirmed c linical trial results from study of VASCEPA in China are expected by year end 2020 : Assuming positive results from this study conducted by Amarin’s commercial partner for VASCEPA in China, regulatory submission in China could follow promptly thereafter. commercial team. “In . 4.3.

Production 40

Production FDA Trials Licensing 40